224 related articles for article (PubMed ID: 36801818)
1. TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer.
Xu S; Gao X; Qiu J; Hong F; Gao F; Wang X; Zhang S
Aging (Albany NY); 2023 Feb; 15(4):1052-1073. PubMed ID: 36801818
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
3. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
4. TIPE2 suppresses the tumorigenesis, growth and metastasis of breast cancer via inhibition of the AKT and p38 signaling pathways.
Zhang Z; Liu L; Liu C; Cao S; Zhu Y; Mei Q
Oncol Rep; 2016 Dec; 36(6):3311-3316. PubMed ID: 27779698
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
6. TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.
Wang L; Chen C; Feng S; Tian J
Mol Med Rep; 2018 May; 17(5):7017-7026. PubMed ID: 29568863
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
Zhuang XH; Liu Y; Li JL
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31337688
[TBL] [Abstract][Full Text] [Related]
8. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
[TBL] [Abstract][Full Text] [Related]
9. Circ-PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR-542-3p/CDC5L/PEAK1 pathway.
Zhang C; Li Y; Zhao W; Liu G; Yang Q
Cancer Med; 2020 May; 9(10):3500-3521. PubMed ID: 32167655
[TBL] [Abstract][Full Text] [Related]
10. TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.
Zhu L; Zhang X; Fu X; Li Z; Sun Z; Wu J; Wang X; Wang F; Li X; Niu S; Ding M; Yang Z; Yang W; Yin M; Zhang L; Zhang M
J Transl Med; 2018 Jan; 16(1):7. PubMed ID: 29343267
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
12. TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway.
Lu Q; Liu Z; Li Z; Chen J; Liao Z; Wu WR; Li YW
Oncol Res; 2016; 24(5):305-313. PubMed ID: 27712587
[TBL] [Abstract][Full Text] [Related]
13. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
14. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment.
Mao TL; Fan MH; Dlamini N; Liu CL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541
[TBL] [Abstract][Full Text] [Related]
16. TIPE2 inhibits GC via regulation of cell proliferation, apoptosis and inflammation.
Lin Z; Liu W; Xiao C; Fan Y; Zhuang G; Qi Z
Oncol Rep; 2018 Sep; 40(3):1307-1316. PubMed ID: 30015980
[TBL] [Abstract][Full Text] [Related]
17. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
Yao N; Sun JQ; Yu L; Ma L; Guo BQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
[TBL] [Abstract][Full Text] [Related]
18. TIPE2 functions as a metastasis suppressor via negatively regulating β-catenin through activating GSK3β in gastric cancer.
Wu J; Zhang H; Xu C; Xu H; Zhou X; Xie Y; Tao M
Int J Oncol; 2016 Jan; 48(1):199-206. PubMed ID: 26530498
[TBL] [Abstract][Full Text] [Related]
19. TIPE2, a negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling.
Peng Y; Zhao Q; Zhang H; Han B; Liu S; Han M; Liu S
Oncol Rep; 2016 Apr; 35(4):2480-6. PubMed ID: 26781452
[TBL] [Abstract][Full Text] [Related]
20. TIPE2 inhibits PDGF-BB-induced phenotype switching in airway smooth muscle cells through the PI3K/Akt signaling pathway.
Wang H; Zhong B; Geng Y; Hao J; Jin Q; Zhang Y; Dong L; Gao D; Li J; Hou W
Respir Res; 2021 Aug; 22(1):238. PubMed ID: 34446024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
